Quince Therapeutics (QNCX) Expected to Release Earnings on Tuesday

Quince Therapeutics (NASDAQ:QNCX) is expected to release its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to announce earnings of ($28.02) per share for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($26.00) by $25.41. On average, analysts expect Quince Therapeutics to post $-3 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Quince Therapeutics Price Performance

Shares of NASDAQ:QNCX traded up $0.29 during trading hours on Tuesday, hitting $25.26. 7,922 shares of the company’s stock traded hands, compared to its average volume of 247,951. Quince Therapeutics has a 1 year low of $15.10 and a 1 year high of $909.98. The business has a fifty day moving average price of $19.45 and a 200-day moving average price of $72.58. The firm has a market capitalization of $24.75 million, a P/E ratio of -0.12 and a beta of 1.36.

Hedge Funds Weigh In On Quince Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. XTX Topco Ltd bought a new stake in shares of Quince Therapeutics in the second quarter valued at about $37,000. Bridgeway Capital Management LLC increased its position in Quince Therapeutics by 20.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock valued at $212,000 after purchasing an additional 22,200 shares during the period. Hudson Bay Capital Management LP purchased a new position in Quince Therapeutics during the 4th quarter valued at about $213,000. Quadrature Capital Ltd bought a new stake in shares of Quince Therapeutics in the 4th quarter valued at about $268,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Quince Therapeutics in the 4th quarter valued at about $308,000. Institutional investors own 30.75% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on QNCX shares. Leerink Partners started coverage on Quince Therapeutics in a report on Wednesday, June 24th. They set an “outperform” rating and a $80.00 price objective for the company. Oppenheimer assumed coverage on Quince Therapeutics in a research report on Wednesday, July 29th. They set an “outperform” rating and a $82.00 target price for the company. Cantor Fitzgerald started coverage on shares of Quince Therapeutics in a research note on Tuesday, June 23rd. They set an “overweight” rating and a $80.00 target price for the company. Wall Street Zen upgraded shares of Quince Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, May 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quince Therapeutics in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Quince Therapeutics currently has an average rating of “Hold” and an average target price of $568.40.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.